With the advent of direct-acting antivirals, the rate of sustained virologic response (SVR) after treatment for chronic HCV infection has dramatically increased [1] . However, recent data show that there is cause for concern regarding the potential emergence of viral resistance [2] .
Background
With the advent of direct-acting antivirals, the rate of sustained virologic response (SVR) after treatment for chronic HCV infection has dramatically increased [1] . However, recent data show that there is cause for concern regarding the potential emergence of viral resistance [2] .
Methods
We performed a study to assess the antiviral resistance profile in a series of patients with limited treatment options for chronic HCV infection.
Results
We assessed data from 12 patients (gender ratio 1:1), of which 10 had HCV monoinfection and 2 had HCV+HIV coinfection. The mean age was 43.8 ± 16.5 years (range 19-71 years). Eleven patients were infected with HCV genotype 1b, and one patient had been coinfected with genotype 2a/2c but had spontaneously cleared 2a infection and was now monoinfected with HCV 2c.
Only one patient had IL28-B genotype CC, 4 patients CT and 5 patients TT (in two cases data on IL28-B were not available). Seven of the patients had received prior anti-HCV therapy: 2 with peg-interferon+ribavirin, 2 with faldaprevir-based regimens and 3 with telaprevir-based regimens. Of them, 3 had been non-responders and 4 had been relapsers.
The mean plasma HCV-RNA was 6.1±0.7 log 10 IU/ mL. Patients were distributed over the whole range of fibrosis values on FibroMax, with a slight predominance of advanced fibrosis: F3 (2 patients) and F4 (3 patients).
Resistance to boceprevir or simeprevir was identified in 3/12 cases (fold-change range: 4-24) and 2/12 cases (fold-change range: 32-38), respectively, although none of the patients had received prior therapy with these antivirals.
Resistance to telaprevir was identified in 3/12 cases (surprisingly, none of the cases with telaprevir therapy). Possible resistance was identified in another 6 cases (including cases treated with telaprevir and faldaprevir). The overall fold-change range was 1.8-22.4.
Resistance to faldaprevir was identified in 3/12 cases (surprisingly, none of the cases with faldaprevir therapy), with a fold-change range of 1.2-360.0.
Conclusion
Cross-resistance to HCV protease inhibitors (PI) remains a cause for concern, particularly in patients with history of treatment with HCV PI-based regimens.
